<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02169089</url>
  </required_header>
  <id_info>
    <org_study_id>57047</org_study_id>
    <nct_id>NCT02169089</nct_id>
  </id_info>
  <brief_title>Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial</brief_title>
  <official_title>Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Maryland, College Park</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Winthrop University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atherosclerotic disease, or hardening of the arteries, is characterized by the thickening of&#xD;
      the arterial walls due to fatty deposits in wall and inflammation in the wall of arteries.&#xD;
      High cholesterol, high blood pressure, diabetes, obesity and genetics play an important role&#xD;
      in developing clinical symptoms of atherosclerosis disease. The complications of advanced&#xD;
      atherosclerosis are chronic, slowly progressive and cumulative, resulting in heart attack,&#xD;
      stroke and/or death and blockage of arteries.&#xD;
&#xD;
      This study is being done to assess the effectiveness of Spironolactone therapy to slow down&#xD;
      the worsening of atherosclerotic disease (hardening of the arteries) in aorta (this is a&#xD;
      large vessel coming out of your heart) compared to placebo (look alike sugar pill). This will&#xD;
      be checked by comparing before and after therapy magnetic resonance imaging (MRI) pictures of&#xD;
      your aortic wall.&#xD;
&#xD;
      Spironolactone is an FDA approved drug used to treat heart failure and in the management of&#xD;
      hypertension (high blood pressure), but in this study it is used for another unapproved&#xD;
      reason. In this study, we would like to evaluate the effects of Spironolactone in people with&#xD;
      diabetes and atherosclerotic disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in atheroma volume (PAV) in the thoracic aorta of Spironolactone vs. placebo</measure>
    <time_frame>56 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central aortic blood pressure of Spironolactone vs. placebo.</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour mean systolic blood pressure of Spironolactone vs. placebo</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity (PWV) of Spironolactone vs. placebo</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of insulin resistance (HOMA-IR) of Spironolactone vs. placebo</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spironolactone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>Patients will be given Spironolactone 12.5 mg on week 0 (visit 2). Patients will be escalated to 25 mg daily Spironolactone or maximal tolerated dose over a 4-week period. Patients will continue treatment for an additional 48 weeks.</description>
    <arm_group_label>Spironolactone</arm_group_label>
    <other_name>Aldactone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients &gt;45 or &gt;40 years with known atherosclerotic events (examples&#xD;
             include MI, Stroke) and able to provide informed consent (females must be either&#xD;
             post-menopausal for one year, surgically sterile, or using effective contraception.&#xD;
             Oral contraceptives are disallowed.&#xD;
&#xD;
          2. Patients with Type II Diabetes with HbA1c ≤ 9.0 on stable anti-glycemic regimen that&#xD;
             may include oral and/or injectable therapy (GLP-1/Insulin etc.). Changes in dose of&#xD;
             glycemic regimen is allowed during the course of the trial if felt to be clinically&#xD;
             appropriate.&#xD;
&#xD;
          3. GFR &lt;90 and evidence of proteinuria (Urine albumin/creatinine ratio of &gt;30 mg/g or&#xD;
             equivalent) in a urine specimen within 12 months OR GFR &lt;60 mg/g regardless of&#xD;
             proteinuria.&#xD;
&#xD;
          4. Patients must be on ACE and/or ARB therapy with no planned dose adjustments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled hypertension (SBP&gt;160 and/or DBP&gt;95 mmHg at visit 0 (screening) and SBP&#xD;
             &gt;145 mm Hg at visit 2).&#xD;
&#xD;
          2. GFR (MDRD) of &lt;15 at Visit 0 (screening).&#xD;
&#xD;
          3. Hyperkalemia defined as serum K+≥ 5.1 meq/L at visit 0 (screening).&#xD;
&#xD;
          4. LDL cholesterol &gt;150 mg/dl.&#xD;
&#xD;
          5. Plasma triglycerides &gt;400 mg/dl.&#xD;
&#xD;
          6. Contraindications to MRI (metallic implants, severe claustrophobia).&#xD;
&#xD;
          7. Acute coronary syndrome, Transient ischemic attack, CVA or critical limb ischemia&#xD;
             during the last 6 months or coronary/peripheral revascularization within the last 3&#xD;
             months.&#xD;
&#xD;
          8. Evidence of a secondary form of hypertension.&#xD;
&#xD;
          9. Initiation of new therapy with statins, ACEI/ARB, anti-oxidants, CCBs, diuretics, β&#xD;
             blockers.&#xD;
&#xD;
         10. Type I diabetes mellitus&#xD;
&#xD;
         11. Known contraindication, including history of allergy to Spironolactone.&#xD;
&#xD;
         12. . Any surgical or medical condition which might alter pharmacokinetics of drug (e.g.&#xD;
             renal transplant, liver failure, liver transplant).&#xD;
&#xD;
         13. Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.&#xD;
&#xD;
         14. Significant hyponatremia defined as Na &lt;130 meq/L.&#xD;
&#xD;
         15. History of prior malignancy including leukemia and lymphoma (but not basal cell skin&#xD;
             cancer, cured squamous cell cancer and localized Prostate cancer).&#xD;
&#xD;
         16. History of any severe, life-threatening disease.&#xD;
&#xD;
         17. Any surgical or medical conditions which places the patient at higher risk derived&#xD;
             from his/her participation into the study, or likely to prevent patient from complying&#xD;
             with requirements.&#xD;
&#xD;
         18. History of drug abuse within the last 2 years, noncompliance and&#xD;
             unwillingness/inability to consent.&#xD;
&#xD;
         19. Pregnant women and nursing mothers.&#xD;
&#xD;
         20. Class III or IV Congestive Heart Failure.&#xD;
&#xD;
         21. Primary Hyperaldosteronism.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>41 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Rajagopalan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief, Cardiovascular Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Conger</last_name>
    <phone>216-866-6550</phone>
    <email>Heather.Conger2@uhhospitals.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steven Sawicki</last_name>
    <phone>216-844-7188</phone>
    <email>steven.sawicki@uhhospitals.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Conger</last_name>
      <phone>216-866-6550</phone>
      <email>heather.conger2@uhhospitals.org</email>
    </contact>
    <contact_backup>
      <last_name>Steven Sawicki</last_name>
      <phone>216-844-7188</phone>
      <email>steven.sawicki@uhhospitals.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjay Rajagopalan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mirela Dobre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Sanjay Rajagopalan</investigator_full_name>
    <investigator_title>Chief, Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

